|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013089,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0205208,
umls-concept:C0205390,
umls-concept:C0445550,
umls-concept:C0450442,
umls-concept:C0599894,
umls-concept:C1143119,
umls-concept:C1521801,
umls-concept:C1801960,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-7-15
|
|
pubmed:abstractText |
Asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF) is a vascular targeting agent exploiting a tumour-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13, overexpressed on tumour blood vessels. Significant preclinical synergy was shown between low doses of NGR-TNF and doxorubicin.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-11062439,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-12189241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-15650236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-16397040,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-17178843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-17577017,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-17875749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-1834117,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-2499653,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-2924376,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19568235-9449699
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1532-1827
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
21
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
219-24
|
|
pubmed:dateRevised |
2010-9-27
|
|
pubmed:meshHeading |
pubmed-meshheading:19568235-Adult,
pubmed-meshheading:19568235-Aged,
pubmed-meshheading:19568235-Aged, 80 and over,
pubmed-meshheading:19568235-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19568235-Dose-Response Relationship, Drug,
pubmed-meshheading:19568235-Doxorubicin,
pubmed-meshheading:19568235-Female,
pubmed-meshheading:19568235-Humans,
pubmed-meshheading:19568235-Male,
pubmed-meshheading:19568235-Middle Aged,
pubmed-meshheading:19568235-Neoplasms,
pubmed-meshheading:19568235-Recombinant Fusion Proteins,
pubmed-meshheading:19568235-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
|
|
pubmed:affiliation |
Department of Oncology, Istituto Scientifico San Raffaele, Via Olgettina, 60, Milan 20132, Italy. gregorc.vanesa@hsr.it
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase I
|
